Knee Osteoarthritis
Conditions
Keywords
KOA, Mesenchymal Stromal Cells
Brief summary
This clinical study is to investigate the safety and efficacy of NCR100 injection in subjects with knee osteoarthritis (KOA). It is a dose-escalating, open label study in adult KOA subjects.
Detailed description
Knee osteoarthritis (KOA) is a kind of degenerative joint disease and there are over 300 million cases worldwide. The aim of this clinical trial is to evaluate the safety, tolerability, and efficacy of human pluripotent stem cell derived mesenchymal stromal cells (NCR100) injection in the treatment of subjects with knee osteoarthritis.
Interventions
BIOLOGICALNCR100 injection
Subjects will receive a one-dose intra-articular NCR100 injection.
Sponsors
Shanghai 6th People's Hospital
Beijing Luhe Hospital
Nuwacell Biotechnologies Co., Ltd.
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Subjects who understand and voluntarily sign the Informed Consent Form（ICF） before the enrolment; * Age: 40-80 years old, both genders; * Diagnosis of knee osteoarthritis based on American College of Rheumatology criteria; * Subjects with KOA who have persistent pain for more than six months, or aggravation or recurrence of osteoarthritis after routine medication; * Kellgren-Lawrence grade: II-III; * McMaster Universities Osteoarthritis Index (WOMAC): 24-72.
Exclusion criteria
* Subjects previously diagnosed of secondary knee osteoarthritis, or those diagnosed with hip/ankle joint disease requiring medical intervention; * Subjects who suffering from other diseases that cause damage to knee joint function or affect joints; * Subjects who have received allogeneic mesenchymal progenitor (stem/stromal) cell therapy; * Subjects who have history of knee joint injury; * Subjects who have undergone knee arthroscopic surgery; * Subjects who received painkillers ( eg,opioids/nonsteroidal anti-inflammatory analgesics ) to treat knee osteoarthritis; * Subjects who have orally taken traditional Chinese medicine; * Subjects who have received intra-articular drug injection to treat knee osteoarthritis; * Subjects with glucosamine, chondroitin sulfate, or diacetate therapy before investigational drug intervention * Subjects with acute reactive knee osteoarthritis; * Severe eversion deformity in target knee joint; * Known or suspected allergy or a history of allergies; * Subjects with abnormal results of laboratory examination: Hepatic Insufficiency (ALT \> 2xULN or Aspartate aminotransferase（AST） \> 2xULN), renal dysfunction (creatinine clearance rate ≤60ml/min or blood urea nitrogen(BUN) \> 2× ULN), Coagulation Defects (INR \> 1.5) or severe hematological diseases (Grade 3 or above anemia Hb \< 8 g/dL, Grade 2 or above thrombocytopenia platelet count(PLT) \< 75×10\^9/L) ; * BMI≥30 kg/m\^2 ; * Severe systemic infection or local knee joint infection; * Subjects who have received systemic glucocorticoid therapy before intervention or need to take systemic glucocorticoid therapy during the treatment; * Subjects who have history of acute myocardial infarction or with heart diseases e.g.uncontrolled angina pectoris, uncontrolled arrhythmias, severe heart failure (NYHA \> III), QT prolongation, and are determined by investigators as not suitable to participate in this clinical trial; * Subjects with peripheral or central nervous system disorders that may interfere with knee joint pain and functional assessment, * Subjects who have contraindications to MRI; * Subjects who have poor physical condition and are unable to walk autonomously; * Subjects with alcohol or drug addiction or with a clear history of mental disorders or with a history of drug abuse or drug use of psychotropic substances; * Subjects with infection with hepatitis B virus(HBV), hepatitis C virus(HCV), HIV, and treponema pallidum confirmed by laboratory tests; * Pregnant or lactating female subjects, or subjects who are unable to comply with contraceptives from the study period to 6 months after the end of this study; * Subjects who have participated in other clinical trials and have used other study products; * Subjects with severe and poorly controlled comorbidities and not suitable for this clinical trial; * Subjects who are not suitable for this clinical trial for other reasons.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Event(AE) or Serious Adverse Event(SAE) | Week1,Week2,Week4 | Number of participants with treatment-related adverse events or serious adverse events as assessed by CTCAE v5.0 |
| Dose-Limiting Toxicity(DLT) | 4 weeks after injection | Number of participants with Dose-limiting toxicity in 28 days after injection |
Secondary
| Measure | Time frame |
|---|---|
| Maximum plasma concentration(Cmax) | 30minutes before administration,24hours,1week,2week,4week,8week,12week and 24week after administration |
| Elimination half life of drug(T1/2) | 30minutes before administration,24hours,1week,2week,4week,8week,12week and 24week after administration |
| Time after doing at which maximun plasma concentration is reached(Tmax) | 30minutes before administration,24hours,1week,2week,4week,8week,12week and 24week after administration |
| Area under the plasma concentration-time curve(AUC) | 30minutes before administration,24hours,1week,2week,4week,8week,12week and 24week after administration |
Contacts
Primary ContactXiaowen Gong
Outcome results
None listed